Ingenol Mebutate 0.06% Gel for Field Treatment of Actinic Keratosis on 250 cm2 of Skin on Trunk and Extremities: A Randomized Dose-Finding Trial
Main Article Content
Background: Field treatment of actinic keratosis (AK) can eradicate clinical and sub-clinical lesions; treatments for extended skin areas are required.
Methods: This randomized, double-blind, vehicle-controlled trial (NCT01998984) evaluated ingenol mebutate (IngMeb) 0.06% gel for AK treatment over extended areas. Adults with 5–20 AK lesions within a 250 cm2 area of skin on the trunk (except chest) or extremities were randomized to: 2 days vehicle, 2 days IngMeb (2D, n=55); 1 day vehicle, 3 days IngMeb (3D, n=59); 4 days IngMeb (4D, n=49); or 4 days vehicle (n=61). Week 8 primary endpoint was complete clearance of AK lesions; secondary endpoints included reduction in AK count and partial clearance. Adverse events (AEs) were recorded and local skin responses (LSRs) assessed. A hierarchical testing scheme, starting with 3D versus vehicle, was used.
Results: In total, 224 patients were randomized. At Week 8, for 2D, 3D, 4D, and vehicle groups, complete clearance rates were 12.7%, 5.1%, 26.8%, and 0.0% (3D vs. vehicle, p=0.18); reductions in AK count were 63.0%, 66.8%, 73.6%, and 11.9%, respectively. LSR scores peaked at Day 5 (3D and 4D), and Days 5 and 10 (2D). Application-site pain and pruritus were common AEs. Of 15 neoplasm AEs, 14 were designated keratoacanthomas and one squamous cell carcinoma by central pathological review. The 4D group was closed based on pre-defined criteria.
Conclusions: All three regimens were effective at reducing AK count on trunk/extremities. The 4D treatment was not well tolerated. Complete clearance was not significantly different to vehicle.
2. Einspahr JG, Stratton SP, Bowden GT, et al. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 2002;41:269-85.
3. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013;169(3):502-18.
4. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115:2523-30.
5. Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging 2013;8:29-35.
6. Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb) 2014;4:11-31.
7. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-8.
8. Malvehy J. A new vision of actinic keratosis beyond visible clinical lesions. J Eur Acad Dermatol Venereol 2015;29(Suppl 1):3-8.
9. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366:1010-9.
10. Lebwohl M, Shumack S, Gold LS, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratosis. JAMA Dermatol 2013;149:666-70.
11. Hanke CW, Berman B, Swanson N, et al. Dose-finding clinical study with ingenol mebutate for field treatment of actinic keratosis up to 250 cm2 on full face, scalp, or chest (PA15), Seminars in Cutaneous Medicine and Surgery 2015;(34) (Supplement 6):S107-108.
12. Rosen R, Marmur E, Anderson L, et al. A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic KeratosisTherapy with Ingenol Mebutate. Dermatol Ther (Heidelb) 2014;4(2):207–219.
13. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel trial of chronic disease. Health and quality of life outcomes 2004;2(1):12.
14. Tanghetti E1, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007;6:144-7.
15. Ostertag JU, Quaedvlieg PJF, van der Geer S, et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratosis. Lasers Surg Med 2006;38:731-9.
16. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006;5:156-9.
17. Berman B, Nestor MS, Newburger J, et al. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALAPDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. J Drugs Dermatol 2014;13:1353-6.
18. Swanson N, Smith CC, Kaur M, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol 2014;13:166-9.
19. Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010;62:573-81.
20. Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 2013;8:35-41.
21. Stockfleth E, Peris K, Guillen C, et al. A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. Int J Dermatol 2015;54:509-15.
22. Campalani E, Holden CA. Keratoacanthoma associated with the use of topical imiquimod. Clin Exp Dermatol 2013;38(5):555-6.
23. Cox S. Rapid development of keratoacanthomas after a body peel. Dermatol Surg 2003;29(2):201-3.
24. Kaptanoglu AF, Kutluay L. Keratoacanthoma developing in previous cryotherapy site for solar keratosis. J Eur Dermatol Venereol 2006;20(2):197-8.
25. Selmer J, Skov T, Spelman L, Weedon, D. Squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review. Histopathology 2016;69(4):535-41.
26. Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-kB: A blossoming of relevance to human pathobiology. Cell 2017;168:37–57.
27. Li ZJ, Sohn KC, Choi DK, et al. Roles of TLR7 in activation of NF-κB signaling of keratinocytes by imiquimod. PLoS One 2013;8(10):e77159.
28. Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25(51):6817-30.
29. Poligone B, Hayden MS, Chen L, Pentland AP, Jimi E, Ghosh S. A role for NF-κB activity in skin hyperplasia and the development of keratoacanthomata in mice. PloS one 2013;8(8):e71887.
30. Costanzo M, Baryshnikova A, Bellay J, et al. The genetic landscape of a cell. Science 2010;327(5964):425-31.
31. Dajee M, Lazarov M, Zhang JY, et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. 2003;421(6923):639-43.
32. Seitz CS, Lin Q, Deng H, Khavari PA. Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB. Proceedings of the National Academy of Sciences 1998;95(5):2307-12.
33. van Hogerlinden M, Rozell BL, Ährlund-Richter L, Toftgård R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-κB signaling. Cancer Res 1999;59(14):3299-303.
34. Holmes C, Foley P, Freeman M, Chong AH. Solar keratosis: epidemiology, pathogenesis, presentation, and treatment. Australas J Dermatol 2007;48(2):67-76.
35. Alam M. Actinic keratoses: prevalence, pathogenesis, presentation, and prevention. Adv Stud Med 2006;6(8A):S785-90.
36. Esmann S, Jemec GB. Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat 2007;18(1):53-8.
37. Tennvall GR, Norlin JM, Malmberg I, et al. Health related quality of life in patients with actinic keratosis--an observational study of patients treated in dermatology specialist care in Denmark. Health Qual Life Outcomes 2015;13:111.